Martin Kulldorff, PhD, is a biostatistician in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital. His current research centers on developing new statistical methods for post-market drug and vaccine safety surveillance.
He has developed new sequential statistical methods for near real-time post-market drug and vaccine safety surveillance, where the purpose is to use weekly, monthly or other frequent data feeds to find potential safety problems as soon as possible. He has developed a tree-based scan statistic for post-market drug and vaccine safety surveillance. Keeping the outcome definitions flexible, the method simultaneously evaluates thousands of potential adverse events and groups of related events, adjusting for the multiple testing inherent in such an approach. Another more recent area of methodological work is the development of new statistical methods for evaluating the comparative safety of different childhood vaccine schedules. A fourth major area of methodological research is spatial and spatio-temporal disease surveillance, for which Dr. Kulldorff has developed various scan statistics for disease cluster detection and investigation; and for the early detection of infectious disease outbreaks.
As a biostatistician, Dr. Kulldorff also do collaborative and consulting work with epidemiologists and clinicians, using a wide variety of study designs and methods for many different types of diseases.
Dr. Kulldorff received his bachelor’s degree in mathematical statistics from Umeå University in Sweden, and his doctorate in operations research from Cornell University.